VERRICA PHARMACEUTICALS INC

VRCANASDAQ

🏆 #3349 by market capEarnings Nov 13US Equity

$525.50▲ $45.93 (+8.74%)

Simulated price

1h—

24h▲ 8.7%

7d—

14d—

30d—

1y—

🏦Market Cap

$90M

Small Cap

📈Revenue Growth (YoY)

+417.6%

High Growth

📊Gross Margin

89.5%

High

💵FCF Margin

—

⚖️P/S Ratio

2.3x

Cheap

Otter Score

Fair

No chart data available for VRCA.

Trading Snapshot

Day Range: $518.01 – $533.19
52-Week Range: $3.28 – $9.82
Volume: $4.74B
Avg Volume: $4.31B
Shares Outstanding: 17.2M
Next Earnings: Sep 29, 2026

Fundamentals Snapshot

Annual Revenue: $36M
Last Q Revenue: $6M
P/E Ratio: —
P/S Ratio: 2.3x
EPS (TTM): $-1.03
Dividend Yield: —

Why Investors Own VRCA

✓High-growth profile — revenue up +1.4% YoY with expanding US Equity exposure.
✓Healthy economics — 78% gross margin and 21% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$36M▼ −3.2% YoY

Gross Margin (TTM)

78.0%▲ +1.3% YoY

Operating Income (TTM)

$11M▼ −3.2% YoY

Free Cash Flow (TTM)

$8M▼ −3.2% YoY

About VERRICA PHARMACEUTICALS INC

Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for use in malignant and pre-malignant dermatological indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.

🦦